Danaher Corporation (DHR)
|Net Income (ttm)||5.45B|
|Trading Day||July 29|
|Day's Range||293.01 - 298.69|
|52-Week Range||191.85 - 298.69|
Does Danaher (DHR) have what it takes to be a top stock pick for momentum investors? Let's find out.
DHR, CLFD, HCA, FBP, and SNBR qualified as the day's Momentum Picks Using Driehaus Strategy.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Cytiva and Pall Corporation investing 1.5 billion USD over two years to meet growing demand for biotechnology solutions
AMERSHAM, United Kingdom, July 27, 2021 /PRNewswire/ -- An ongoing strategic growth plan from Cytiva and Pall Corporation, part of the Danaher (NYSE: DHR) Corporation, will expand manufacturing capacity...
BREA, Calif., July 26, 2021 /PRNewswire/ -- Beckman Coulter, a global clinical diagnostics leader, today announced that it has entered into definitive agreements with Quidel Corporation to obtain all ri...
Danaher's (DHR) Q2 results reflect strength in segmental businesses, the impact of pandemic-led tailwinds and improved margins. Projection for core sales growth, including Cytiva, increases for 2021.
Danaher (DHR) delivered earnings and revenue surprises of 20.59% and 7.83%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Danaher Corporation (NYSE: DHR) logged a higher profit for the second quarter as its sales grew. Adjusted EPS increased 71% Y/Y to $2.46, surpassing the estimate of $2.05.
WASHINGTON, July 22, 2021 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (the "Company") today announced results for the second quarter 2021. All results in this release reflect only continuing operat...
The stock price of Danaher, a conglomerate with products in environmental, life sciences, and diagnostics fields, has seen a 10% rise over the last twenty-one trading days, while it is up 47% over the l...
Danaher (NYSE:DHR) unveils its next round of earnings this Thursday, July 22. Get prepared with Benzinga's ultimate preview for Danaher's Q2 earnings.
FSS vs. DHR: Which Stock Is the Better Value Option?
Danaher (DHR) Q2 performance is likely to have gained from the pandemic-induced demand for products, focus on innovation and synergistic gains from acquired assets.
Danaher (DHR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Danaher (DHR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
WASHINGTON, June 22, 2021 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the second quarter 2021 on Thursday, July 22, 2021 beg...
When the operating income margin continues to expand, it means that the company is becoming more efficient in generating profits from its operations.
Danaher (DHR) to gain from the Aldevron acquisition as it will increase growth opportunities in the genomic medicine field. The acquired assets will be integrated with Danaher's Life Sciences segment.
Danaher (DHR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down ...
FRAMINGHAM, Mass.--(BUSINESS WIRE)-- #beextraordinary--SCIEX OS introduces new software with OneOmics suite in SCIEX Cloud and Molecule Profiler app.
FRAMINGHAM, Mass.--(BUSINESS WIRE)-- #SCIEX--SCIEX presents the ZenoTOF 7600 system, a new accurate mass LC-MS/MS instrument that features the proprietary Zeno trap and EAD fragmentation.
If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider Danaher (DHR).
Danaher Corporation (NYSE: DHR) has agreed to acquire privately-held Aldevron for a cash purchase price of approximately $9.6 billion. Danaher expects to finance the acquisition using cash on hand or pr...
WASHINGTON, June 17, 2021 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (the "Company") announced today that Danaher has entered into a definitive agreement to acquire privately-held Aldevron, for a c...
We have narrowed down our search to five corporate bigwigs that have provided better returns than the S&P 500 Index in the past three months. These are: FDX, SHW, DHR, TGt and NVDA.
The Dow Jones ticked up 20 points, the S&P 500 rose 0.1%, and the Nasdaq gained 0.2%. Make the most of today's market with the Top Buys from Q.ai's artificial intelligence.
1800 FLOWERS.COM (FLWS), Polaris (PII) & Danaher (DHR) are some of the top stocks that have striking earnings growth and positive estimate revisions at present.
Danaher (DHR) possesses solid growth attributes, which could help it handily outperform the market.
To protect one's portfolio from suffering huge losses, investors mostly choose stocks that bear low leverage. You may buy HZO, TITN, SPH, DHR and TD.
Danaher (DHR), with an 11% rise in shares in the past three months, gains from solid product offerings, the pandemic-induced demand and focus on innovation. Inorganic activities too have been aiding.
WASHINGTON, June 7, 2021 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that Executive Vice President and Chief Financial Officer, Matt McGrew, will be presenting at the Goldman Sachs Global ...
WASHINGTON, May 27, 2021 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that Executive Vice President and Chief Financial Officer, Matt McGrew, will be presenting at the Jefferies Healthcare ...
There's a lot to like about the life sciences and diagnostics company, even after the COVID-19 pandemic.
WASHINGTON, May 13, 2021 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced today that it has appointed A. Shane Sanders to its Board of Directors and to its Audit Committee.
WASHINGTON, May 5, 2021 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced today that its Board of Directors has approved a regular quarterly cash dividend of $0.21 per share of its common stock,...
WASHINGTON, May 4, 2021 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that President and Chief Executive Officer, Rainer M. Blair, will be presenting at the Bank of America Healthcare Confer...
FSS vs. DHR: Which Stock Is the Better Value Option?
The life sciences and diagnostics company is a big winner of the COVID-19 pandemic.
The life sciences and diagnostic company is set up for another great year.
WASHINGTON, April 26, 2021 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) ("Danaher"), the global science and technology company, announced today the formation of a Scientific Advisory Board ("Board") ...
Danaher's (DHR) first-quarter 2021 revenues increase 57.9% year over year on account of impressive performance across its segments.
Danaher (DHR) delivered earnings and revenue surprises of 50.90% and 0.57%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Shares of Danaher (NYSE:DHR) moved higher by 0.2% in pre-market trading after the company reported Q1 results. Quarterly Results Earnings per share rose 140.00% year over year to $2.52, which beat the e...
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company operates through three segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment provides mass spectrometers; cellular analysis, lab automation, and centrifugation instruments; microscopes; and genomics consumables. This segment also offers bioprocess technologies, consumables, and services; and filtration, separation, and purification technologies to t... [Read more...]
Diagnostics & Research
|Stock Exchange |
|Ticker Symbol |
In 2020, Danaher's revenue was $22.28 billion, an increase of 24.42% compared to the previous year's $17.91 billion. Earnings were $3.65 billion, an increase of 21.21%.
According to 21 analysts, the average rating for Danaher stock is "Buy." The 12-month stock price forecast is 292.32, which is a decrease of -1.78% from the latest price.